Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
24.67
+0.84 (3.52%)
At close: Aug 21, 2026, 4:00 PM EDT
24.18
-0.49 (-1.99%)
After-hours: Aug 21, 2026, 6:29 PM EDT

Pacira BioSciences Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, Pacira BioSciences stock has a consensus rating of "Buy" and an average price target of $30. The average 1-year stock price forecast is 21.61% higher than the current stock price, while the lowest is $23 (-6.77%) and the highest is $38 (+54.03%).

Price Target: $30 (+21.61%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$23$30$30$38
Change-6.77%+21.61%+21.61%+54.03%

Analyst Ratings

The average analyst rating for Pacira BioSciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy333222
Buy111111
Hold222222
Sell111111
Strong Sell000000
Total777666

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Barclays
Barclays
Hold
Maintains
$25
HoldMaintains$25+1.34%Aug 17, 2026
J.P. Morgan
J.P. Morgan
Sell
Maintains
$23
SellMaintains$23-6.77%Aug 10, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$38
BuyReiterates$38+54.03%Aug 5, 2026
RBC Capital
RBC Capital
Hold
Maintains
$24$25
HoldMaintains$24$25+1.34%Aug 5, 2026
Needham
Needham
Buy
Maintains
$32$33
BuyMaintains$32$33+33.77%Aug 5, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
752.96M
from 726.41M
Increased by 3.65%
Revenue Next Year
788.21M
from 752.96M
Increased by 4.68%
EPS This Year
2.88
from 2.65
Increased by 8.81%
EPS Next Year
3.45
from 2.88
Increased by 19.65%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
541.53M666.82M674.98M700.97M726.41M752.96M
Revenue Growth
26.04%23.14%1.22%3.85%3.63%3.65%
Gross Profit
401.28M467.53M490.31M530.54M576.66M592.77M
Gross Margin
74.10%70.11%72.64%75.69%79.39%78.73%
Operating Income
89.92M70.93M87.32M97.57M33.30M155.53M
Net Income
41.98M15.91M41.96M-99.56M7.03M50.62M
EPS
----2.652.88
EPS Growth
-----17.19%8.81%
Forward PE
15.4311.6410.237.107.538.56
Free Cash Flow
49.79M92.00M107.15M163.38M108.56M195.25M
No. Analysts
-----6
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High759.4M
Avg753.0M
Low747.8M

Revenue Growth

Revenue Growth202620272028
High
4.5%
Avg
3.7%
Low
2.9%

EPS Forecast

EPS202620272028
High2.99
Avg2.88
Low2.72

EPS Growth

EPS Growth202620272028
High
12.8%
Avg
8.8%
Low
2.5%